Ishigaki K - Search Results

1

Characteristic findings of skeletal muscle MRI in caveolinopathies.

Ishiguro K, Nakayama T, Yoshioka M, Murakami T, Kajino S, Shichiji M, Sato T, Hino-Fukuyo N, Kuru S, Osawa M, Nagata S, Okubo M, Murakami N, Hayashi YK, Nishino I, Ishigaki K. Ishiguro K, et al. Among authors: ishigaki k. Neuromuscul Disord. 2018 Oct;28(10):857-862. doi: 10.1016/j.nmd.2018.07.010. Epub 2018 Jul 31. Neuromuscul Disord. 2018. PMID: 30174172

2

TRH therapy in a patient with juvenile Alexander disease.

Ishigaki K, Ito Y, Sawaishi Y, Kodaira K, Funatsuka M, Hattori N, Nakano K, Saito K, Osawa M. Ishigaki K, et al. Brain Dev. 2006 Nov;28(10):663-7. doi: 10.1016/j.braindev.2006.05.001. Epub 2006 Jun 13. Brain Dev. 2006. PMID: 16774812

3

Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.

Kajimoto H, Ishigaki K, Okumura K, Tomimatsu H, Nakazawa M, Saito K, Osawa M, Nakanishi T. Kajimoto H, et al. Among authors: ishigaki k. Circ J. 2006 Aug;70(8):991-4. doi: 10.1253/circj.70.991. Circ J. 2006. PMID: 16864930 Free article. Clinical Trial.

4

Creatine monohydrate therapy in a Leigh syndrome patient with A8344G mutation.

Komura K, Nakano K, Ishigaki K, Tarashima M, Nakayama T, Sasaki K, Saito K, Osawa M. Komura K, et al. Among authors: ishigaki k. Pediatr Int. 2006 Aug;48(4):409-12. doi: 10.1111/j.1442-200X.2006.02231.x. Pediatr Int. 2006. PMID: 16911089 No abstract available.

5

Modified Atkins diet therapy for a case with glucose transporter type 1 deficiency syndrome.

Ito S, Oguni H, Ito Y, Ishigaki K, Ohinata J, Osawa M. Ito S, et al. Among authors: ishigaki k. Brain Dev. 2008 Mar;30(3):226-8. doi: 10.1016/j.braindev.2007.08.006. Epub 2007 Sep 14. Brain Dev. 2008. PMID: 17869467

6

Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis.

Ishigaki K, Shishikura K, Murakami T, Suzuki H, Hirayama Y, Osawa M. Ishigaki K, et al. Brain Dev. 2009 Sep;31(8):634-7. doi: 10.1016/j.braindev.2008.08.016. Epub 2008 Oct 9. Brain Dev. 2009. PMID: 18845408

7

[Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency].

Ishigaki K, Murakami T, Ito Y, Yanagisawa A, Kodaira K, Shishikura K, Suzuki H, Hirayama Y, Osawa M. Ishigaki K, et al. No To Hattatsu. 2009 Jan;41(1):37-42. No To Hattatsu. 2009. PMID: 19172815 Japanese.

8

High-density areas on muscle CT in childhood-onset Pompe disease are caused by excess calcium accumulation.

Ishigaki K, Mitsuhashi S, Kuwatsuru R, Murakami T, Shishikura K, Suzuki H, Hirayama Y, Nonaka I, Osawa M. Ishigaki K, et al. Acta Neuropathol. 2010 Oct;120(4):537-43. doi: 10.1007/s00401-010-0732-8. Epub 2010 Aug 3. Acta Neuropathol. 2010. PMID: 20680637

9

Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease.

Ishigaki K, Murakami T, Nakanishi T, Oda E, Sato T, Osawa M. Ishigaki K, et al. Brain Dev. 2012 Feb;34(2):98-102. doi: 10.1016/j.braindev.2011.05.004. Epub 2011 Jun 14. Brain Dev. 2012. PMID: 21676566

10

High-density CT of muscle and liver may allow early diagnosis of childhood-onset Pompe disease.

Ishigaki K, Yoshikawa Y, Kuwatsuru R, Oda E, Murakami T, Sato T, Saito T, Umezu R, Osawa M. Ishigaki K, et al. Brain Dev. 2012 Feb;34(2):103-6. doi: 10.1016/j.braindev.2011.05.013. Epub 2011 Jun 24. Brain Dev. 2012. PMID: 21704464

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

319 results

Search Page